JP2016505053A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505053A5
JP2016505053A5 JP2015554039A JP2015554039A JP2016505053A5 JP 2016505053 A5 JP2016505053 A5 JP 2016505053A5 JP 2015554039 A JP2015554039 A JP 2015554039A JP 2015554039 A JP2015554039 A JP 2015554039A JP 2016505053 A5 JP2016505053 A5 JP 2016505053A5
Authority
JP
Japan
Prior art keywords
title compound
esi
minutes
starting
prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015554039A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505053A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2014/071206 external-priority patent/WO2014114249A1/en
Publication of JP2016505053A publication Critical patent/JP2016505053A/ja
Publication of JP2016505053A5 publication Critical patent/JP2016505053A5/ja
Pending legal-status Critical Current

Links

JP2015554039A 2013-01-25 2014-01-23 Lp‐PLA2の阻害剤としての二環式ピリミドン化合物 Pending JP2016505053A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013070977 2013-01-25
CNPCT/CN2013/070977 2013-01-25
PCT/CN2014/071206 WO2014114249A1 (en) 2013-01-25 2014-01-23 Bicyclic pyrimidone compounds as inhibitors of lp-pla2

Publications (2)

Publication Number Publication Date
JP2016505053A JP2016505053A (ja) 2016-02-18
JP2016505053A5 true JP2016505053A5 (cg-RX-API-DMAC7.html) 2016-07-14

Family

ID=51226939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015554039A Pending JP2016505053A (ja) 2013-01-25 2014-01-23 Lp‐PLA2の阻害剤としての二環式ピリミドン化合物

Country Status (9)

Country Link
US (1) US20150344485A1 (cg-RX-API-DMAC7.html)
EP (1) EP2948456A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016505053A (cg-RX-API-DMAC7.html)
KR (1) KR20150108896A (cg-RX-API-DMAC7.html)
AU (1) AU2014210260B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015017397A2 (cg-RX-API-DMAC7.html)
CA (1) CA2899143A1 (cg-RX-API-DMAC7.html)
RU (1) RU2015135824A (cg-RX-API-DMAC7.html)
WO (1) WO2014114249A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106536525B (zh) * 2014-07-22 2019-05-03 葛兰素史密斯克莱知识产权发展有限公司 化合物
CN105777653A (zh) * 2014-12-26 2016-07-20 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的嘧啶酮类化合物及其药物组合物
CN106188063A (zh) * 2015-05-08 2016-12-07 中国科学院上海药物研究所 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途
CN105001098B (zh) * 2015-07-26 2016-09-14 嵊州市油脂化工有限公司 一种3(r)/(s)-氨基-1-丁醇的制备方法
SG11202012131VA (en) 2018-06-08 2021-01-28 Attabotics Inc Improved storage and retrieval systems
CN110683960A (zh) * 2019-08-22 2020-01-14 台州达辰药业有限公司 一种(r)-3-氨基丁醇的合成方法
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
BR9510420A (pt) 1994-12-22 2004-04-20 Smithkline Beecham Plc Azetidin-2-onas substituìdas para o tratamento de aterosclerose
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
HUP9901153A3 (en) 1995-07-01 1999-11-29 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis, their production and pharmaceutical compositions containing them
WO1997012963A2 (en) 1995-09-29 1997-04-10 Smithkline Beecham Plc A paf-acetylhydrolase and use in therapy
JP2000505063A (ja) 1995-12-08 2000-04-25 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のためのアゼチジノン化合物
EP0869943A1 (en) 1995-12-08 1998-10-14 Smithkline Beecham Plc Monocyclic beta-lactame derivatives for treatment of atherosclerosis
IL126696A0 (en) 1996-04-26 1999-08-17 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis
GB9608649D0 (en) 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
DE69816471T2 (de) 1997-11-06 2004-05-27 Smithkline Beecham P.L.C., Brentford Pyrimidinon verbindungen und diese enthaltende pharmazeutische zusammenstellungen
EP1105377B1 (en) 1998-08-21 2003-10-08 SmithKline Beecham plc Pyrimidinone derivatives for the treatment of atherosclerosis
WO2000066567A1 (en) 1999-05-01 2000-11-09 Smithkline Beecham Plc Pyrimidinone compounds
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
GB9910378D0 (en) 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds
JP3757703B2 (ja) 1999-09-22 2006-03-22 凸版印刷株式会社 再封可能な開口維持部材付パウチ
PT1263740E (pt) 2000-02-16 2006-11-30 Smithkline Beecham Plc Derivado de pirimidin-4- ona como inibidor de ldl-pla2
GB0024807D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0119793D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0119795D0 (en) 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel process
GB0127139D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127143D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127140D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127141D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Plc Novel compounds
GB0208279D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208280D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
CA2530816A1 (en) 2003-07-02 2005-01-13 Bayer Healthcare Ag Amide-substituted 1,2,4-triazin-5(2h)-ones for the treatment of chronic inflammatory diseases
DE102004061008A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one
DE102004061009A1 (de) 2004-12-18 2006-06-22 Bayer Healthcare Ag Substituierte 1,2,4-Triazin-5(2H)-one
US20080090851A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080090852A1 (en) 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US7705005B2 (en) 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
JP2010506852A (ja) * 2006-10-13 2010-03-04 グラクソ グループ リミテッド 二環式ヘテロ芳香族化合物
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
US20080279846A1 (en) 2007-05-11 2008-11-13 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
US9029383B2 (en) 2007-05-11 2015-05-12 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
JP2011088847A (ja) * 2009-10-21 2011-05-06 Takeda Chem Ind Ltd 三環性化合物およびその用途
EP2619203A4 (en) * 2010-09-20 2014-04-16 Glaxo Group Ltd TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND APPLICATIONS THEREOF
EP2649050A4 (en) * 2010-12-06 2014-04-23 Glaxo Group Ltd LINKS
JP2013545792A (ja) 2010-12-17 2013-12-26 グラクソ グループ リミテッド 眼疾患の処置および防止方法
CA2843102A1 (en) * 2011-07-27 2013-01-31 Glaxo Group Limited Bicyclic pyrimidone compounds

Similar Documents

Publication Publication Date Title
JP2016505053A5 (cg-RX-API-DMAC7.html)
JP2016505058A5 (cg-RX-API-DMAC7.html)
JP6963557B2 (ja) 4−((6−(2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−2−ヒドロキシ−3−(1h−1,2,4−トリアゾール−1−イル)プロピル)ピリジン−3−イル)オキシ)ベンゾニトリル及び調製方法
IL259400A (en) 4 - ((6- (2- (4,2-difluorophenyl) -1,1-difluoro-2-oxoethyl) pyridin-3-yl) oxy) benzonitrile and processes for its preparation
JP2017507982A (ja) 2−(2,4−ジフルオロフェニル)−1,1−ジフルオロ−1−(5−置換−ピリジン−2−イル)−3−(1h−テトラゾール−1−イル)プロパン−2−オールおよびその調製工程
US20180370946A1 (en) 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
GEP20186886B (en) Oxidation reaction with excellent conversion rate
Kasai et al. A Practical Synthesis and Applications of (E)-Diphenyl-β-(trifluoromethyl) vinylsulfonium Triflate
JP2016516744A5 (cg-RX-API-DMAC7.html)
AU2018366342A1 (en) Method for preparing Baricitinib
JP5077969B2 (ja) 2−置換5−(1−アルキルチオ)アルキルピリジンの調製方法
TWI303632B (en) Process for preparing pyridazinone compounds
JP2017526665A (ja) 光学活性イソキサゾリン化合物の製造プロセス
WO2012121345A1 (ja) 有機基で置換された含フッ素オレフィンの製造方法
CN102584801B (zh) Hiv逆转录酶抑制剂依法韦伦类化合物的一锅法不对称合成工艺
CN108026014A (zh) 光学活性的2-(2-氟联苯-4-基)丙酸的制备方法
US8063226B2 (en) Process for preparing 2-amino-4-(haloalkyl) pyridine derivatives by cyclizing suitable nitrile precursors with nitrogen compounds
JP6240346B2 (ja) ロスバスタチンカルシウムを製造するための中間体化合物、及びそれを用いてロスバスタチンカルシウムを製造する方法
CN104045596A (zh) 制备依托考昔中间体1-(6-甲基吡啶-3-基)-2-[4-(甲磺酰基)苯基]乙酮的新方法
CN103588600A (zh) 一种空气氛围中铜催化有机硼酸化合物脱除硼酸基的方法
CN105503955B (zh) 一种抗革兰氏阳性菌的化合物的制备方法
JP4239462B2 (ja) ピリドン化合物の製造法およびその中間体
JP2014195753A (ja) モノメチル硫酸塩のアルカリ性水溶液の処理方法
JP2008500316A (ja) 抗菌薬の中間体としてのアリール置換されたオキサゾリジノンの製造方法
CN100352821C (zh) 一种瑞舒伐他汀钙中间体的制备方法